Moderna Stock Soars After Promising New Vaccine Data—Is Now the Time to Buy?

Moderna stock (NASDAQ: MRNA) traded at $62.96 at Tuesday’s close and ticked up to $63.45 in after-hours action, keeping the messenger-RNA pioneer in focus as Wall Street digests a wave of fresh catalysts. On 5 August the U.S. Food and Drug Administration granted full approval to mRNA-1010, the first-ever mRNA influenza vaccine, while Moderna simultaneously posted second-quarter results that showed 9 % revenue growth year over year but a wider net loss tied to launch costs and pipeline spend. Paradoxically, shares slipped more than 4 % the following session as traders fretted over margin pressure despite the regulatory win. Still, the stock is up roughly 80 % since January after optimism about the flu asset, an RSV filing expected later this year and early oncology readouts reignited risk-on appetite among biotech investors. Management now projects full-year revenue to climb “up to 10 %,” helped by commercial launches and new government contracts for updated COVID boosters. Analysts are split. Bulls argue that the flu approval validates Moderna’s platform and opens a multibillion-dollar seasonal market, while bears warn that profitability may stay elusive until fixed manufacturing costs are absorbed by a broader product lineup. According to Reuters consensus, the average 12-month price target sits near $78, implying moderate upside from current levels. Key levels to watch: $66 (recent resistance coinciding with the 200-day moving average) and $60 (psychological support). A decisive break above $66 could clear a path toward the June peak near $72, whereas a dip below $60 might invite profit-taking back to the mid-$50s range. Bottom line: With the first mRNA flu shot in hand, a rich clinical slate and a stock still trading more than 70 % below its 2021 pandemic high, Moderna remains one of 2026’s most closely watched healthcare stories. Traders chasing near-term momentum should brace for earnings-driven swings, while long-term investors will be laser-focused on how quickly management can translate its expanding pipeline into recurring, diversified revenue streams.